Veru Inc. Reports Fiscal 2025 First Quarter Financial Results and Clinical Program ProgressVERU INC. (NASDAQ: VERU) recently released its financial results for the first quarter of fiscal 2025, along with key updates on its clinical development progr
This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Veru’s 8K filing here. Veru Company Profile (Get Free Report) Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress […]
This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Veru’s 8K filing here. Veru Company Profile (Get Free Report) Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress […]
